Scribe Biosciences, Inc.

San Francisco, CA 94107
www.scribebiosciences.com/
info@scribebiosciences.com

SINCE ITS FOUNDING IN

2017

6 SBIR Awards

4 Employees

N/A Socioeconomic Category

5 Pending Patent from SBIR/STTR

A Platform for Viral Evolution Assays

Before we can replace conventional, static therapies for disease with dynamic cell-based ones, we will need high-throughput screening platforms that can identify rare cells with unique capabilities.

Scribe Biosciences created a platform that performs single cell experiments with minimal agents, enabling long term evolutionary studies. Operating at the level of single cells enables Scribe to quickly identify and then extensively study rare variances from large populations under complex conditions. The platform manipulates droplets with printed microfluidics, providing a more microscopic study of rare viral mutants. The smallness of the droplets in which they culture and evolve single viruses requires minimal reagents and greatly expands the number of experiments that can be conducted.

Printed Droplet Microfluidics



Deterministic Cell Delivery



Single Cell Viral Passaging



Solicitation:
New Platform Technologies for Viral and Therapeutic Evolution Assays

DARPA SBIR Sponsor
SB171-003 Topic Number
New capabilities Primary Innovation
Reliability Secondary Innovation

IMPACT TO THE MISSION

The platform will provide a tool for the rapid development of countermeasures to an emerging viral pandemic threat. The technology will enable the culture and selection of rare viral variants with unique properties, a capability not possible with current bulk culturing methods.

BEYOND PHASE II

Scribe is commercializing the core technology as a discovery platform for new cancer immunotherapies. The platform will be sold as a benchtop research instrument and a suite of disposables that enables single cell functional assays and single cell genomics. Scribe has raised $500k in angel investment funding with $2.4M from Casdin Capital, Formic Ventures, and Harmonix Fund.

This research was developed with funding from the Defense Advanced Research Projects Agency (DARPA). The views, opinions and/or findings expressed are those of the author(s) and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government." (Approved for Public Release. Distribution Unlimited 07/23/21)